Vudalimab is under clinical development by Xencor and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vudalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XmAb-717 is under development for the treatment of cervical cancer, squamous cell carcinoma of the anus, melanoma, triple-negative breast cancer, high-grade neuroendocrine carcinoma, squamous cell carcinoma of the penus, hepatocellular carcinoma, urothelial cell carcinoma, renal cell carcinoma, colorectal cancer, endometrial cancer, non-small cell lung carcinoma, prostate cancer, mesothelioma, gastroesophageal junction carcinomas, gastric cancer, small cell carcinoma of the lung, head and neck cancer squamous cell carcinoma, nasopharyngeal cancer, cholangiocarcinoma, gall bladder cancer, basal cell carcinoma, ovarian cancer, fallopian tube cancer, peritoneal cancer, thymic carcinoma, vulvar cancer, salivary gland cancer, thymoma, Hodgkin Lymphoma, anaplastic thyroid cancer, spindle cell squamous cell carcinoma, HER2 negative breast cancer and non-small cell lung cancer . It is administered through intravenous route. The drug candidate is a bi-specific monoclonal antibody that acts by targeting programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It is developed based on XmAb bi-specific/ Xtend Fc domains antibody engineering technology. It was under development for the treatment of anal cancer.
Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.
For a complete picture of Vudalimab’s drug-specific PTSR and LoA scores, buy the report here.